TLDR Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
This study evaluated the efficacy of ritlecitinib, a selective JAK3 and TEC family inhibitor, in treating adolescents with moderate-to-severe alopecia areata (AA). Conducted as a single-center, retrospective observational study, it included 11 patients aged ≥ 12 years, treated with ritlecitinib 50 mg daily for 24 weeks. Results showed that 27.3% of patients achieved near-complete hair regrowth (SALT ≤ 10), and 45.5% showed substantial improvement (SALT ≤ 20) by Week 24. Significant reductions in SALT scores were observed as early as Week 8. Eyebrow and eyelash improvements were also noted, with no serious adverse events reported. These findings align with previous trial data, suggesting ritlecitinib as a promising treatment for adolescent AA, though larger studies are needed to confirm these results.
January 2023 in “Journal of The American Academy of Dermatology” Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
2 citations
,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
October 2024 in “Journal of Education Health and Sport” Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
138 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
